Novo Nordisk: Back To Business School
www.forbes.com
May 10, 2024, 2:41 p.m.
In the Man Markets Meeting this week, the great Rory Powe – soon to celebrate a decade at Man Group - spoke eloquently about Novo Nordisk, a firm whose GLP-1 semaglutide treatments for diabetes (Ozempic) and obesity (Wegovy) are only the most high-profile of its increasingly diverse range of drugs. The firm has more than 80% of the global weight management industry, notwithstanding competition from the likes of Eli Lilly and Company. Its rocketing share price has reflected the fact that it has not only attained this dominant market position, but also appears to have a strong pipeline of next generation drugs: Amycretin, currently undergoing trials, is being touted as significantly more effective than Wegovy, allowing patients to lose more weight, more swiftly.